E-Mail
IMAGE: Senior author and Princess Margaret Scientist Dr. Marianne Koritzinsky s research reveals the potential of targeted therapies to exploit unique metabolic features of pancreatic cancer cells. view more
Credit: Visual Services, UHN
(Toronto, Friday, May 7, 2021) Probing the unique biology of human pancreatic cancer cells in a laboratory has yielded unexpected insights of a weakness that can be used against the cells to kill them.
Led by Princess Margaret Cancer Centre (PM) Scientist Dr. Marianne Koritzinsky, researchers showed that about half of patient-derived pancreatic cancer cell lines are highly dependent or addicted to the protein peroxiredoxin 4 (PRDX4), as a result of the altered metabolic state of the cancer cell.